Core Viewpoint - The article discusses the ongoing dispute between two major players in the beauty industry, Juzi Biotechnology and Huaxi Biotechnology, focusing on Juzi's acknowledgment of limitations in their collagen product standards and their plans for improvement [2][8]. Group 1: Juzi Biotechnology's Response - Juzi Biotechnology admitted that their current quality standards, testing methods, and labeling have limitations that do not fully meet the high standards and requirements of industry development and technological advancement [2][8]. - The company plans to collaborate with research institutions to accelerate the optimization and validation of qualitative and quantitative testing methods for recombinant collagen in cosmetics [8]. - Juzi will gradually disclose key technical parameters and quality control data for raw materials and finished products to empower industry development and accept public supervision [8]. Group 2: Industry Standards and Developments - The latest industry standard for recombinant collagen dressings, YY/T 1947-2025, is set to be implemented in March 2026, indicating a need for updated compliance among companies [6]. - Juzi Biotechnology emphasized the necessity for continuous optimization and iteration of their quality standards and methods in response to the rapid development of the recombinant collagen industry and increasing consumer quality demands [8]. Group 3: Huaxi Biotechnology's Position - Huaxi Biotechnology previously addressed concerns regarding the lack of relevant testing standards in the recombinant collagen field, highlighting the misuse of the term "collagen" in the market [9]. - They criticized the misleading use of the term "collagen" by some companies, which do not produce the actual collagen sequence and structure, thus lacking physiological functionality [9]. - Huaxi believes that clear and scientifically verifiable conclusions are essential to avoid prolonged disputes and help companies resolve their issues quickly [9].

Core Viewpoint - The ongoing controversy regarding the content of recombinant collagen products from Giant Bio (02367.HK) remains unresolved, with the company not directly addressing anonymous criticisms from testing agencies [1][2]. Group 1: Company Response and Actions - On June 23, Giant Bio acknowledged the limitations of its current quality standards and announced a technical improvement plan in response to market discussions about its recombinant collagen products [2][3]. - The company has conducted a comprehensive self-inspection of its production, testing, and packaging processes, and is validating different testing methods to address recent controversies [3]. - Giant Bio plans to collaborate with research institutions to optimize qualitative and quantitative testing methods for cosmetic recombinant collagen, and will gradually disclose key technical parameters and quality control data [3][4]. Group 2: Industry Standards and Market Impact - Giant Bio has been a pioneer in the recombinant collagen field since applying for a patent in 2001, and it adheres to various industry standards that have been implemented from 2021 to 2025 [3]. - The company's recent statement led to a rebound in its stock price, although it has experienced significant volatility over the past month, dropping from a high of 85.14 HKD on May 20 to 54.6 HKD by June 24 [4]. - The company's market capitalization has decreased by nearly 30 billion HKD from its previous peak, now standing at 584.7 billion HKD [5].

Core Viewpoint - The 2025 New Fortune 500 Rich List reveals a significant increase in the total market value of listed entrepreneurs, reaching 13.7 trillion yuan, an 11% year-on-year growth, indicating a new wave of wealth creation driven by innovation and overseas expansion [3][14]. Group 1: Wealth Distribution and Rankings - The top ten wealthiest individuals are heavily influenced by AI, with Zhang Yiming of ByteDance topping the list with a holding value of 481.57 billion yuan, marking a 42% increase from the previous year [4][18]. - The list features a notable shift, with four individuals from Hangzhou, Zhejiang, highlighting the region's growing economic prominence [43]. - The average holding value of the 500 entrepreneurs is 273.8 million yuan, with a threshold of 66.2 million yuan to make the list [8]. Group 2: Industry Insights - The TMT (Technology, Media, and Telecommunications), pharmaceutical, and daily consumer goods sectors are the top three wealth-generating industries, contributing 110, 54, and 52 individuals respectively [51]. - The TMT sector saw a significant increase in wealth, with a total of 334.08 billion yuan, a 46% increase from the previous year [51]. - The pharmaceutical sector experienced a decline, with 54 individuals listed, down from 64, indicating ongoing valuation adjustments [51]. Group 3: AI and Technological Advancements - AI has emerged as a key driver of wealth creation, with companies like DeepSeek and ByteDance leading the charge in user engagement and valuation [4][21]. - The rise of AI has also led to a resurgence in the semiconductor industry, with China exporting 2.981 billion chips worth approximately 159.5 billion USD, marking a significant shift in the global market [56]. - The AI sector is still in its nascent stage, with notable entries like Liang Wenfeng of DeepSeek entering the top ten, reflecting the rapid growth and potential of AI applications [60]. Group 4: Regional Wealth Creation - Wealth creation is becoming more balanced across regions, with western provinces like Sichuan, Tibet, and Xinjiang seeing an increase in listed individuals, while traditional economic hubs like Zhejiang and Shanghai continue to grow [5][6]. - The shift from real estate to technology and AI reflects a broader transformation in China's economic landscape, with younger entrepreneurs increasingly dominating the wealth rankings [46][45]. Group 5: Future Outlook - The ongoing evolution of industries, particularly in AI and technology, suggests a promising future for innovation-driven wealth creation in China [60][62]. - The integration of AI into various sectors, including automotive and consumer electronics, is expected to further enhance China's competitive edge in the global market [62][63].

Core Viewpoint - The company, Xi'an Juzhi Biological Gene Technology Co., Ltd. (referred to as "Juzhi Biological"), has issued a statement addressing controversies surrounding its recombinant collagen product, Kefu Mei, emphasizing its commitment to quality standards and ongoing improvements in response to industry developments [1][2]. Group 1: Company Background and Standards - Juzhi Biological applied for the first domestic invention patent related to recombinant collagen in 2001, naming the innovative substance "human-like collagen" and applying for the "human-like" trademark [1]. - The company has accumulated over 20 years of technical expertise, transitioning the substance from laboratory research to industrial application [1]. - Multiple industry standards related to recombinant collagen have been established, including the 2021 "Guidelines for Naming Recombinant Collagen Biological Materials" and the 2022 medical industry standard YY/T 1849-2022 [1]. Group 2: Quality Control and Self-Inspection - The company claims that its product development and production adhere to established standards, implementing quality control measures for raw materials and products [2]. - In response to the controversies, Juzhi Biological conducted a comprehensive self-inspection of all production, testing, and labeling processes, validating different testing methods [2]. - The company acknowledged limitations in its existing quality standards and testing methods, indicating a need for continuous optimization to meet evolving industry standards [2]. Group 3: Controversy and Response - The controversy began when a beauty blogger accused Juzhi Biological's Kefu Mei product of ingredient fraud, claiming the actual collagen content was only 0.0177% [3]. - Juzhi Biological refuted these claims, stating that their testing results showed collagen content exceeding 0.1%, contradicting the blogger's assertions [3]. - The dispute centers on differing testing methods, with both parties accusing each other of using "unscientific" approaches, as there are currently no national standards for testing recombinant collagen in cosmetics [3]. Group 4: Market Impact - As of June 23, Juzhi Biological's total market value was HKD 54.83 billion, reflecting a nearly 40% decline from its peak on May 20 [4].

Core Viewpoint - The company has issued a statement regarding the standards and developments related to recombinant collagen products, highlighting the need for continuous improvement in quality standards and testing methods to meet industry demands and consumer expectations [1][2]. Group 1: Industry Standards - In 2021, the guideline for naming recombinant collagen biomaterials was published and implemented [1] - In 2022, the pharmaceutical industry standard YY/T 1849-2022 for recombinant collagen was published and implemented [1] - In 2023, the pharmaceutical industry standard YY/T 1888-2023 for recombinant humanized collagen was published and implemented [1] - In 2023, the group standard T/ZGKSL 004-2023 for recombinant collagen raw materials used in cosmetics was published and implemented [1] - In 2025, the pharmaceutical industry standard YY/T 1947-2025 for recombinant collagen dressings is set to be published, with implementation in March 2026 [1] Group 2: Company Response and Actions - The company has conducted a comprehensive self-inspection of all aspects of production, testing, and labeling in response to recent discussions about the recombinant collagen content in its products [1] - The company acknowledges the limitations of its current quality standards, testing methods, and labeling, which need to be optimized to align with industry advancements and high consumer expectations [2] - The company plans to collaborate with research institutions to accelerate the optimization and validation of qualitative and quantitative testing methods for recombinant collagen in cosmetics [2] - The company aims to gradually disclose key technical parameters and quality control data for raw materials and finished products to empower industry development and accept public supervision [2] - The company will continue to participate in the formulation of national and industry standards related to recombinant collagen in cosmetics to promote standardized industry development [2]

Investment Rating - Industry rating: Recommended [5] Core Insights - The beauty sector experienced a stable conclusion during the 618 shopping festival, with significant changes in platform and brand dynamics driven by reduced commission policies and interest-based content ecosystems [1][2] - The total GMV for beauty products across four major e-commerce platforms (Taobao, JD, Douyin, Kuaishou) during the 618 period was between 600-700 billion yuan, reflecting a year-on-year growth of over 10% [1] - Taobao maintained the largest market share at 41.3%, followed by Douyin at 35.7%, JD at 14.8%, and Kuaishou at 8.2% [1][13] Summary by Sections E-commerce Platform Dynamics - Douyin's beauty segment is rapidly growing, supported by merchant subsidies and interest-driven consumer engagement, achieving double-digit growth [2] - Douyin's promotional strategies included a 1.4 billion yuan subsidy for merchants in May, with individual merchant reductions reaching up to 2.99 million yuan [2] Skincare and Makeup Categories - In the skincare category, domestic brands like Proya and Han Shu led the market, maintaining their top positions on Taobao and Douyin [3] - The top five brands in the skincare category on Taobao remained stable, with Proya and Han Shu continuing to dominate [3] - In the makeup and fragrance category, new domestic brands are emerging, with Ti Luo Wei achieving rapid growth by focusing on base makeup products [4] International and Domestic Brand Strategies - International brands are performing well due to localized marketing strategies and a willingness to engage with local consumers [8] - Domestic brands are expected to break out of the competitive cycle focused on ingredients and efficacy, emphasizing brand influence and comprehensive user experience [8] Investment Recommendations - Focus on domestic companies with strong brand equity and comprehensive channel strategies, particularly Proya and Han Shu [9] - Highlight technology-driven skincare brands like Betaini and Juzi Biology that target specific consumer needs [9] - Consider daily chemical brands with strong cost-performance ratios and excellent management of emerging channels, such as Runben and Dengkang [9]

Core Viewpoint - The recent debate in the medical beauty industry regarding "recombinant collagen" has led to significant stock price fluctuations for leading companies, particularly Huaxi Biological and Juzhi Biological, with Huaxi denying any "business war" motives behind its actions [1][5]. Group 1: Market Reactions and Company Performance - From May 24 to June 18, Huaxi Biological's stock price increased by 23.65%, while Juzhi Biological's stock price fell by over 31% during the same period [1]. - As of June 18, Juzhi Biological's market capitalization was approximately 514 billion RMB, while Huaxi Biological's market capitalization was 245 billion RMB, less than half of Juzhi's [1]. Group 2: Opposition to "Name Games" - Huaxi Biological firmly opposes the "name game" in ingredient labeling, arguing that the capital market's concept switching has led to misunderstandings about hyaluronic acid and recombinant collagen, affecting the business environment and causing resource misallocation [2][3]. - The company emphasizes that recombinant collagen is only a small part of collagen research and that the leading edge of protein research remains with life science institutions and pharmaceutical companies [3]. Group 3: Industry Standards and Scientific Communication - Huaxi Biological highlights that no medical beauty Class III device certificates based on recombinant collagen have been approved internationally, indicating that this field requires more time for practical observation [3]. - The company plans to enhance professional communication with the capital market, noting that many analysts lack a biological background and often misinterpret the relationship between hyaluronic acid and collagen [4]. Group 4: Denial of Business War Claims - Huaxi Biological denies rumors that its recent actions are motivated by a "business war" due to pressure on its hyaluronic acid business and competition losses in recombinant collagen [5][6]. - The company asserts that its business has not been under pressure as claimed, with hyaluronic acid business growing over 10% annually and medical-grade hyaluronic acid growing over 20% [6]. Group 5: Consumer Trust and Market Integrity - Huaxi Biological argues that consumer trust in domestic brands should not be built on the misuse of academic concepts and misleading marketing practices, which could distort the business ecosystem and lead to resource misallocation [7]. - The company calls for industry-wide participation in product testing and standard discussions to enhance understanding and eliminate industry bubbles and misconceptions [7]. Group 6: Timeline of Events - The controversy began in mid-May when Huaxi Biological questioned several brokerage reports that promoted recombinant collagen and criticized hyaluronic acid [8]. - On May 24, beauty blogger "Big Mouth Doctor" Hao Yu publicly questioned the collagen content in Juzhi Biological's products, leading to further disputes [9][10].

Group 1 - The State Council of China, led by Premier Li Qiang, is promoting the replication of pilot measures from the China (Shanghai) Free Trade Zone and is reviewing new models for real estate development [2] - The U.S. stock market experienced a decline, with major indices falling over 1%, including the Dow Jones down 1.79% and the Nasdaq down 1.3% [2] - International gold prices rose, with spot gold increasing by 1.4% to $3433.35 per ounce, while oil prices also surged, with WTI crude oil up 7.55% to $73.18 per barrel [3] Group 2 - The European stock indices all fell, with Germany's DAX down 1.07% and France's CAC40 down 1.04% [4] - As of the end of May, China's M2 money supply reached 325.78 trillion yuan, growing by 7.9% year-on-year, while M1 increased by 2.3% [5] - The China Securities Regulatory Commission has issued new regulations for the management of algorithmic trading in the futures market, effective from October 2025 [6] Group 3 - The Ministry of Industry and Information Technology is seeking public opinions on the "Automobile Data Export Security Guidelines (2025 Edition)" [7] - The Chinese defense ministry has expressed strong dissatisfaction with Japan's recent military provocations and has called for an end to such actions [8] - The official report on the "Luo Mouyu Fall Incident" indicates that the case was ruled a suicide, with investigations ongoing [8] Group 4 - Guizhou Moutai announced an adjustment to its profit distribution plan for 2024, increasing the cash dividend per share from 27.624 yuan to 27.673 yuan [14] - Tencent has clarified that it is not considering acquiring Nexon, dispelling market speculation [15] - Ant Group has changed its legal representative to CEO Han Xinyi, while the core management team remains unchanged [16] Group 5 - Huaxia Happiness's debt restructuring has faced challenges, with a significant portion of shareholders opposing a key proposal [19] - Zijin Mining reported that its largest copper mine, Kamoa-Kakula, is expected to see a production decrease of over 22% year-on-year due to operational suspensions [25] - The company Chasing has denied rumors regarding a failed bet and is actively addressing false information spread about it [27]

Core Viewpoint - The controversy surrounding the cosmetic brand "Kefumei" and its alleged false advertising of a collagen product has escalated, leading to significant public attention and legal implications for the involved parties [1][3]. Group 1: Company Responses - "Giant Bio" issued a statement acknowledging the apology from the testing agency used by "Dr. Big Mouth" and emphasized that the agency did not authorize the testing report [4]. - "Giant Bio" reiterated that their product contains real recombinant collagen protein and denied any allegations of false advertising or misleading consumers [5]. - "Huaxi Bio" publicly supported "Dr. Big Mouth," stating that the company is an important member of its ecosystem and has invested in related ventures [4]. Group 2: Influencer Background - "Dr. Big Mouth," whose real name is Hao Yu, is a well-known beauty influencer with over 2.8 million followers across various platforms and holds a PhD in chemistry from the University of Hong Kong [3]. - The influencer's allegations against "Giant Bio" regarding the authenticity of their collagen product gained significant traction, even trending on social media [3]. Group 3: Legal and Regulatory Implications - "Giant Bio" announced intentions to pursue legal action against those spreading false information, highlighting the seriousness of the allegations and the potential impact on their brand [4]. - The testing agency involved has demanded that "Dr. Big Mouth" cease using and sharing the disputed test report to prevent further public misinformation [4].

Core Insights - The medical beauty industry in China is projected to grow, with a consumption penetration rate increasing from 3.2% in 2020 to 5.8% by 2025, indicating over 80 million people have undergone medical beauty procedures [1] - The brand "可复美" (Kefumei) under 巨子生物 (Giant Bio) is facing significant negative publicity due to allegations of product fraud related to its key ingredient, recombinant collagen [2][3] - The controversy has led to a substantial decline in Giant Bio's stock price, dropping nearly 30% from its peak of 87.1 HKD [3][25] Industry Overview - The medical beauty market is expanding rapidly, with a notable increase in consumer engagement and product usage [1] - The competitive landscape is intensifying, particularly with rival companies like 华熙生物 (Huaxi Bio) actively targeting Giant Bio amid the ongoing controversies [4][5] Company Performance - Giant Bio's revenue grew from 20 billion RMB in 2022 to 35.24 billion RMB in 2023, marking a 49.05% increase, and further to 55.39 billion RMB in 2024, with a 57.2% year-on-year growth [25] - Despite strong revenue growth, the company has faced challenges in maintaining investor confidence due to recent scandals, leading to a market capitalization drop of over 60 billion HKD [3][25] Product Controversies - The allegations against Kefumei include claims that the amount of recombinant collagen in its products is significantly lower than advertised, raising questions about product integrity [3][6] - Previous controversies involved undisclosed ingredients like epidermal growth factor (EGF), which is banned in cosmetic products, further complicating the brand's reputation [10][12][17] Market Dynamics - The ongoing disputes have prompted consumers to reconsider their loyalty to Kefumei, with potential shifts towards alternative brands like 修丽可 (Xiu Li Ke) and 敷尔佳 (Fu Er Jia) [27] - The company's reliance on sales and marketing over research and development is evident, with a stark contrast between sales expenses and R&D investment, which may impact long-term sustainability [28][29]